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Abstract
Rationale: Extracellular vesicles (EVs) play a significant role in cell-cell communication. However, whether

and how extracellular vesicles are involved in chronic intermittent hypoxia-induced endothelial dysfunction is
unknown.

Methods: Comparative transcriptomics analysis and miRNA screening were used to identify the possible

pathways or target molecules mediating chronic intermittent hypoxia-induced endothelial function. Serum- or
erythrocyte-derived EVs were isolated through ultracentrifugation plus filtration. After in vitro or in vivo
treatment with EVs, aortic rings were treated with dihydroethidium staining for superoxidative anion
measurement or mounted with wire myography to measure isometric forces. Immunoblotting and qPCR were
used for evaluating the molecular mechanism mediating EV miR-144-induced endothelial function under
intermittent hypoxia.

Results: We revealed a previously undefined importance of circulating extracellular vesicles in regulating

endothelial function via delivery of miR-144 to endothelial cells, reducing nuclear factor erythroid 2-related
factor 2 expression. Additionally, we identified that erythrocytes were the primary cellular source of
miR-144-enriched serum-derived extracellular vesicles and that erythrocyte-derived extracellular vesicles
were largely responsible for chronic intermittent hypoxia-impaired endothelial function. Furthermore,
silencing of miR-144 by anti-miR-144 confirmed its essential role in endothelial dysfunction elicited by
erythrocyte-derived extracellular vesicles from chronic intermittent hypoxia-exposed C57BL/6 mice.

Conclusion: The results expand the scope of blood-borne substances involved in vascular homeostasis and

suggest that anti-miR-144-loaded extracellular vesicles may represent a promising therapeutic approach against
obstructive sleep apnea or chronic intermittent hypoxia-associated endothelial dysfunction.
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Introduction
Obstructive sleep apnea (OSA), hallmarked with
chronic intermittent hypoxia (CIH) due to recurrent
partial or complete pharyngeal collapse during sleep,
is a highly prevalent chronic sleep disorder. OSA is
identified as an independent risk factor for the
development of systemic hypertension. Approxi-

mately 50% of OSA patients are hypertensive and an
estimated 70-85% patients with resistant hypertensive
patients have OSA [1]. However, the precise
mechanisms underlying OSA-induced hypertension
are only partially understood. Growing evidence has
revealed that vascular endothelial dysfunction,
https://www.thno.org

Theranostics 2022, Vol. 12, Issue 9
characterized by impaired endothelium-dependent
relaxations, is the earliest sign of vascular injury
preceding the occurrence of clinically obvious
cardiovascular complications in OSA [2]. Therefore, a
holistic analysis of the molecular mechanism of
endothelial dysfunction under CIH status will help to
fully understand the pathogenesis of OSA-or
CIH-associated hypertension.
Oxidative stress leads to endothelial dysfunction
by promoting NO uncoupling. Anti-oxidative
transcription factor NRF2 preserves endothelial
function and prevents Ang II-induced hypertension
[3]. It has been reported that CIH induced myocardial
injury by inhibiting NRF2 protein expression [4], but
whether NRF2 mediates CIH-related endothelial
dysfunction and hypertension is still obscure.
The secretion of extracellular vesicles (EVs) into
the blood or other body fluids is a universal cellular
process that occurs in multicellular organisms. EVs, as
a vital mediator of intercellular communication,
perform multifaceted functions by delivering complex
molecules to recipient cells, thus participating in the
regulation of multiple physiological and pathological
process [5]. Endothelial cells are the primary cell type
known to take up EVs. Circulating EVs, which are in
direct and constant contact with endothelial cells, can
be absorbed by endothelial cells, thereby affecting the
regulation of angiogenesis [6], vascular permeability
[7], and vascular tone [8]. Previous literature
documented that circulating exosomal miR-144-3p
inhibited the mobilization of endothelial progenitor
cells and then impaired neovascularization in
diabetes-related myocardial infarction [9]. However,
few studies concerned the effect and detail the
mechanism of circulating EVs on CIH-related
endothelial dysfunction and hypertension.
In this study, we examined the effects of
serum-derived EVs as well as erythrocyte-derived
EVs from CIH-exposed C57BL/6 mice on
endothelial-dependent relaxation and elucidated the
underlying mechanisms. This research will help to
further understand OSA- or CIH-related endothelial
dysfunction and hypertension from a new
perspective.

Methods
The data that support the findings of this study
are available from the corresponding author upon
reasonable request. See Data Supplement for detailed
methods.

Animal studies
Experiments were approved by Capital Medical
University
Animal
Experimentation
Ethics
Committee and in compliance with the National
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Institutes of Health Guidelines on the Use of
Laboratory Animals. C57BL/6 mice were treated
under normoxia or chronic intermittent hypoxia as
previous report [10]. Endothelial dependent dilation
to acetylcholine was measured.

Molecular biology
EV was isolated from serum and red blood cells
as previous reports [8, 11].

Statistics
Statistical analysis is summarized in the figure
legends. In most cases, the results represent the mean
± standard error of the mean (SEM) of n separate
experiments.
Concentration-response curves were
compared by two-way analysis of variance (two-way
ANOVA) followed by Bonferroni post hoc test.
Two-tailed Student’s t-test was used when two
groups were compared. One-way analysis of variance
(ANOVA) was performed to determine whether there
was a significant difference between more than two
datasets, followed by Bonferroni’s post hoc test. P <
0.05 indicates statistical difference between groups.

Results
Chronic intermittent hypoxia treatment
induces endothelial dysfunction, promotes
superoxide anion radical generation, and
inhibits NRF2 expression
30-day CIH treatment severely attenuated
endothelium-dependent relaxation (EDR) in C57BL/6
mouse thoracic aortas (mean relaxation from 92.1% to
56.4%) and carotid arteries (mean relaxation from
87.3% to 61.8%), and significantly elevated blood
pressure, especially systolic blood pressure, but the
effects were reversed by re-administering normal
oxygen for 15 days after 30-day-CIH treatment
(Figure 1A and Figure S1A-C). CIH treatment
increased blood triglyceride levels, but did not
significantly change glucose tolerance (Figure S1D-F).
To
determine
the
mechanism
underlying
CIH-induced endothelial dysfunction, microarray
analysis was employed to identify differentially
expressed genes in aortas from C57BL/6 mice
exposed to normoxia (N), CIH (C), and normoxic
conditions for 15 days after 30-day-CIH treatment
(Re-Nor post-CIH; R). We identified 743 significantly
differentially expressed coding genes (Table S1,
https://data.mendeley.com/drafts/zbrmjpdv93)
between CIH and normoxia mice, with a concomitant
reverse tendency in the Re-Nor post-CIH group. Gene
ontology (GO) and Kyoto Encyclopedia of Genes and
Genomes (KEGG) enrichment analysis demonstrated
the cellular processing and functions of differentially
expressed genes (Table S2-3). Based on the functional
https://www.thno.org
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characterization, all differentially expressed genes to
be associated with vessel constriction and dilatation,
reactive
oxygen
species
(ROS)
generation,
inflammation, and angiogenesis were manually
categorized and presented with a heat map (Figure 1B
and Figure S2A-B). Of note, a Venn diagram revealed
only one gene, nuclear factor erythroid 2-related
factor 2 (Nrf2), to be implicated in all four of the
above-mentioned functions (Figure 1C). Consistently,
Western-blotting results showed that the levels of
NRF2 and its downstream target, CATALASE (CAT)
were significantly reduced in the aorta from 30-day
CIH-exposed C57BL/6 mice and restored in Re-Nor
post-CIH group (Figure 1D). Meanwhile, 30-day CIH
treatment increased the mRNA levels of NADPH
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oxidase (NOX) complex subunits, Nox2 and p47phox
(Figure S2C). Correspondingly, increased superoxide
production was clearly demonstrated in aortic
endothelial cells from CIH-treated mice detected by en
face fluorescence with dihydroethidium (DHE)
staining, which was reversed by acute 30-min
exposure to the ROS scavengers, Tempol (100 μM) or
Tiron (1 mM) and DETCA (0.1 mM), as well as by oral
treatment with NRF2 agonist, Oltipraz (0.5 g/kg daily
in saline via gavage for 4 days before execution)
(Figure 1E and Figure S2D). Furthermore,
administration of Tempol, Tiron and DETCA, and
Oltipraz reversed CIH-induced impairment of EDR in
C57BL/6 thoracic aorta and carotid arteries (Figure 1F
and Figure S2E).

Figure 1. CIH treatment impairs EDR, reduces NRF2 expression, and promotes superoxide anion production. (A) CIH treatment impaired EDR in mouse
thoracic aortas in a time-dependent manner. (B) Some differentially expressed genes in aortas from C57BL/6 mice treated with normoxia (N), CIH (C), or Re-Nor post-CIH (R)
were predicted to be associated with vessel contraction and dilation, and reactive oxygen species according to GO and KEGG analysis. (C) A Venn diagram illustrated overlap
of genes with predicted functions related to angiogenesis (blue), reactive oxygen species (green), contraction and dilation (orange), and inflammation (yellow). (D) CIH-30d
treatment reduced the expression of NRF2, and its downstream target, CAT, in C57BL/6 mouse aorta, whereas re-administering normoxia for 15 days after 30-day-CIH
treatment restored the decreased expression of NRF2 and CAT induced by CIH. (E) CIH-30d treatment increased superoxide anion production in endothelial cells, as detected
by en face fluorescence with dihydroethidium (DHE) dye (red), which was blocked by 30-min pretreatment with ROS scavengers, Tempol (100 µM), or Tiron (1 mM) and DETCA
(0.1 mM) or NRF2 agonist, Oltipraz (0.5 g/kg in saline, gavage once per day for 4 days). Bar, 20 µm. Green autofluorescence (auto-flu), elastic fibers; Red DHE staining, ROS in
endothelial cells. (F) 30-min pretreatment with ROS scavengers, Tempol (100 µM), Tiron (1 mM) and DETCA (0.1 mM), or 4-day treatment with NRF2 agonist, Oltipraz (0.5
g/kg), reversed CIH-induced endothelial dysfunction in thoracic aortas. Results are the mean ± SEM (n = 4). *P < 0.05 vs. Nor. #P < 0.05 vs. CIH (D and F). Two-way ANOVA (A
and F) and two-tailed t test (D).

https://www.thno.org
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Figure 2. Extracellular vesicles isolated from C57BL/6 mouse serum can be absorbed by aortic endothelial cells. (A) Electron microscopy image of
whole-mount EVs purified from serum extracellular vesicles (S-EVs). Bar, 200 nm. (B) Enrichment of extracellular vesicle markers, CD63, CD81, CD9, ALIX, TSG101, and
Calnexin in different serum protein fractions shown by Western blotting. Silver staining demonstrates protein loading and the protein profile of each sample. (C) S-EV size (111.0
± 57.2 nm) was analyzed by NanoSight NS300. (D) The concentration of S-EVs was measured by NanoSight NS300. (E) Time-dependent uptake of S-EVs by mouse aortic
endothelial cells assessed by en face staining. Nuclei were stained blue with DAPI. S-EVs were stained green by PKH67. Bar, 20 µm. Results are the mean ± SEM (n = 4-5). *P <
0.05 vs. Nor. Two-tailed t test (D).

Serum EVs from CIH-treated C57BL/6 mice
(CIH S-EVs) impair endothelial function,
augment superoxide anion production, and
decrease NRF2 expression
To investigate the effect of CIH S-EVs on EDRs,
we first evaluated the characterization of S-EVs.
Transmission electron microscopy showed that most
S-EVs isolated from normal C57BL/6 mice presented
classic disc-shaped vesicles with a diameter around
100nm (Figure 2A). The EV markers, especially
exosome associated proteins including CD9, CD63,
CD81, ALIX, and TSG101, were enriched in the EV
fraction. The endoplasmic reticulum protein,
Calnexin, was barely detectable in the EV fraction
(Figure 2B). Nanoparticle tracking analysis revealed
S-EVs with an average size 111.0 ± 57.2 nm yield by
300 μL serum (Figure 2C), while the amount CIH
S-EVs was approximately 2-fold that of the normoxic
group (Nor S-EVs) (Figure 2D). En face staining
demonstrated that PKH67-labeled C57BL/6 mouse
S-EVs were taken up by endothelial cells in a
time-dependent fashion (Figure 2E).
Ex vivo treatment for 48 h with CIH serum

(serum from 1 mL of mouse blood made up to a final
volume of 1 mL with serum-free DMEM) attenuated
EDR in mouse aortas, whereas EV-free serum
treatment did not produce such an inhibitory effect.
Direct exposure to CIH S-EVs for 48 h attenuated EDR
in C57BL/6 mouse thoracic aortas and decreased
flow-mediated dilatation in C57BL/6 mouse
mesenteric arteries (Figure 3A-B), but did not affect
the endothelium-independent relaxation in mouse
aortas (Figure S3A). This effect was more pronounced
when aortas were treated with a higher S-EV
concentration, or for a longer period (Figure S3B-C).
Co-treatment with heparin (0.3 μg/mL, blocker of EV
absorption) reversed CIH S-EV-impaired EDR in
mouse aortas (Figure 3C). To further ascertain how
CIH S-EVs exerts the adverse effect on EDR,
transcriptome microarray analysis was used to
identify differentially expressed genes in HUVECs
treated with CIH S-EVs or Nor S-EVs. 19 significantly
differentially expressed coding genes were identified
between the two groups (Figure 3D, upper panel, and
Table
S4,
https://data.mendeley.com/drafts/
xk3krh5ffp). Among them, Nrf2 was the only
differentially expressed gene common to both CIH
https://www.thno.org
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S-EV-treated HUVECs and CIH-treated mouse aortas
(Figure 3D, below panel). Further verification showed
that CIH S-EV ex vivo treatment indeed decreased the
protein expression of NRF2 and its target, CAT, in
both murine endothelial cell line, H5V, (Figure S3D)
and mouse aortas (Figure 3E). Furthermore, 48 h of
CIH S-EV treatment increased superoxide anion
production in H5V cells and in aortic endothelial cells,
an effect blocked by 30-min pretreatment with ROS
scavengers, Tempol or Tiron and DETCA, or the 48-h
cotreatment of NRF2 agonist, Oltipraz (Figure 3F-G
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and Figure S3E-F). Whereas, the mRNA levels of NOX
subunits or Xanthine dehydrogenase (Xdh) were not
altered in CIH S-EV-treated H5V cells (Figure S3G),
indicating that decreased NRF2 was the possible
primary molecular responsible for CIH S-EV-induced
superoxide anion overproduction in endothelial cells.
Consistently, aorta EDR impaired by 48-h CIH S-EVs
treatment was reversed by Tempol, Tiron and DETCA
as well as NRF2 agonist Oltipraz or lentivirusmediated NRF2 overexpression (Figure 3H-I and
Figure S3H).

Figure 3. CIH S-EVs impair endothelial function, augment superoxide anion production, and decrease NRF2 expression in endothelial cells. (A) 48-h
treatment with serum from CIH-treated mouse attenuated EDR in mouse aortas. This effect was absent after removal of EVs from the serum, while 48-h-treatment with CIH
S-EVs isolated from 1 mL of blood significantly impaired EDR in mouse aortas. (B) Exposure (48 h) to CIH S-EVs reduced flow-mediated dilatation in C57BL/6 mouse mesenteric
arteries. (C) Heparin (0.3 µg/mL, 48 h) ameliorated EDR induced by CIH S-EVs. (D) Transcriptome microarray analysis was used to identify differentially expressed genes in
HUVECs treated with CIH S-EVs or Nor S-EVs (up panel). The Venn diagram showed the number of overlapping genes from CIH S-EV-treated HUVECs (orange) and
CIH-treated mouse aortas (green) (below panel). (E) CIH S-EV reduced the expression of NRF2 and CAT in mouse aortas. (F-G) CIH S-EV-incubation increased superoxide
anion production in aortic endothelial cells detected by DHE fluorescent dye, which was blocked by 30-min pretreatment with ROS scavengers, Tempol (100 µM), or Tiron (1
mM) and DETCA (0.1 mM), or NRF2 agonist, Oltipraz (100 µM, co-culture for 48 h). Bar, 50 µm. (H) 30-min pretreatment with ROS scavengers, Tempol (100 µM), or Tiron
(1 mM) and DETCA (0.1 mM), or co-culture with NRF2 agonist, Oltipraz (100 µM) for 48 h reversed CIH S-EV-induced endothelial dysfunction in aortas. (I) CIH S-EV-attenuated
EDR in mouse aortas was absent after Nrf2 overexpression mediated by lentivirus. Results are the means ± SEM (n = 4-9). *P < 0.05 vs. Nor S-EV. #P < 0.05 vs. CIH S-EV. Two-way
ANOVA (A, C, H, I) and two-tailed t test (B, E, G).

https://www.thno.org
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Figure 4. miR-144 is increased in CIH S-EVs, and is delivered to endothelial cells by S-EVs. (A) Relative expression level of indicated miRNAs in CIH S-EV or Nor
S-EV. (B) Diagram depicted the predicted binding sites of miR-27a and miR-144 on the 3’-UTR of Nrf2. (C) AgomiR-144 and agomiR-27a decreased the expression of NRF2 and
CAT in H5V cells. The below panel showed the relative expression level of NRF2 and CAT. (D) The treatment of agomiR-144 plus co-transfection of Nrf2 3'UTR reporter
plasmid led to a significant decrease of the luciferase activity. (E) The expression of miR-144 and miR-27a in S-EV-free medium-cultured H5V cells with 24-h normoxia or
intermittent hypoxia (IH) treatment. (F) Pri-miR-27a and pri-miR-144 were measured by qPCR in EV-free medium-cultured H5V endothelial cells after normoxia or intermittent
hypoxia-treatment for 24 h. (G-H) The expression of miR-144 in S-EV-free medium-cultured H5V cells with 24-h Nor S-EV or CIH S-EV treatment with (H) or without (G)
actinomycin D (10 µg/mL in DMSO) cotreatment. Results are the mean ± SEM (n = 4). *P < 0.05 vs. Nor S-EV (A, G) or Nor S-EV plus actinomycin D or Scr (C, D) or Nor (E,
F). One-way ANOVA (D, G, H) and two-tailed t test (A, C, E, F).

miR-144 is elevated in CIH S-EVs
We have compared the S-EV protein profiles, but
did not identify the possible differentially expressed
S-EV
protein
participating
in
CIH-induced
endothelial dysfunction [12]. To determine the
mechanism by which CIH S-EVs decreased NRF2 and
impaired endothelial function, we measured several
EV-associated miRNAs related to oxidative stress or
hypoxia signaling [13-19] in S-EVs from normoxiaand CIH-treated mice by qPCR. Levels of miR-126
were decreased while those of miR-132, miR-150,
miR-27a, and miR-144 were increased in CIH S-EVs
(Figure 4A). Previous reports [20] as well as miRNA
target prediction by TargetScan indicated conserved
binding sequences for miR-27a and miR-144a in the
3′-UTR of Nrf2 (Figure 4B). Therefore, we detected the
expression regulation of NRF2 by miR-144 and

miR-27a in H5V. As expected, overexpression of
miR-144 and miR-27a using angomiR-144 and
angomiR-27a reduced the protein levels of NRF2 and
its target, CAT, in H5V (Figure 4C) and inhibited
Nrf2-3’UTR-drived luciferase activity in 293A cells
(Figure 4D). Furthermore, qPCR results demonstrated
that mature miR-27a and its primary transcript
pri-miR-27a (but not miR-144 or pri-miR-144), were
induced in H5V after intermittent hypoxia (IH)
treatment for 24 h (Figure 4E-F), suggesting that
miR-27a, other than miR-144 was endogenously
expressed in endothelial cells and responded to IH
stimulus.
miR-144
expression
was
almost
undetectable in H5V cells, but CIH S-EV treatment
significantly increased miR-144 abundance in H5V
cells (Figure 4G). This effect persisted regardless of
whether we inhibited the production of endogenous
miRNAs with actinomycin D (10 µg/mL in DMSO)
https://www.thno.org
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(Figure 4H), suggesting that the endothelial miR-144
signal was mainly from S-EVs. Hence, EV miR-144
was selected as our target molecule for further
investigation.

miR-144 is elevated in erythrocyte-derived
extracellular vesicles from CIH-exposed mice
(CIH E-EVs)
miR-144 is primarily expressed in erythrocytes
and involved in erythroid differentiation [21]. To
clarify the cellular origin of miR-144 in CIH S-EVs,
erythrocyte-derived extracellular vesicles (E-EVs)
were isolated from C57BL/6 mouse red blood cells by
ultracentrifugation and visualized by transmission
electron microscopy. E-EVs presented as classic disc
shape (Figure 5A). Nanoparticle tracking analysis
showed the average diameter of E-EVs was 115.0±50.9
nm (Figure 5B). The purity of the isolated E-EVs was
determined by the relative abundance of
E-EV-resident proteins, including CD9, CD81, and
TSG101. The erythrocyte protein, HBA, was also
observed in the E-EV fraction (Figure 5C). qPCR assay
showed that miR-144 was markedly upregulated in
E-EVs from both CIH-treated C57BL/6 mouse
erythrocytes and OSA patient erythrocytes (Figure
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5D-E and Figure S4A-B).

HIF-1α and GATA1 mediate upregulation of
miR-144 in CIH E-EVs
To provide further evidence of EV-mediated
cell-cell communication between erythrocytes and
endothelial cells, we measured the levels of pri- and
mature miR-144 in red blood cells and endothelial
cells from C57BL/6 mice after normoxia, 30-day CIH,
or normoxic conditions for 15 days after 30-day-CIH
(CIH-R-N) treatment. qPCR results presented that the
expression of miR-144 and pri-miR-144 was dominant
in erythrocytes rather than in endothelial cells. Under
CIH status, the expression of pri-miR-144 and
miR-144 was significantly increased in erythrocytes
and the tendency was reversed after returning to
normoxia for 15 days; whereas, in aortic endothelial
cells, only miR-144 was upregulated (Figure 6A-B),
indicating that miR-144 in endothelial cells was most
likely transferred exogenously from erythrocytes in
vivo. We further studied the molecular regulation of
miR-144 in erythrocytes under hypoxia status.
miR-144 was upregulated in murine erythroleukemia
(MEL) cells after continuous hypoxia, intermittent
hypoxia, or DMOG (1 mM, HIF-1α stabilizer)

Figure 5. Characterization of isolated E-EVs and miR-144 expression in E-EVs. (A) E-EVs isolated from culture medium of mouse red blood cells were imaged by
transmission electron microscopy. Bar, 200 nm. (B) E-EV size (111.0 ± 57.2 nm) was analyzed by NanoSight NS300. (C) Different fractions were processed for Western blotting
with EV markers, CD9, CD63, CD81, and TSG101, endoplasmic reticulum marker, Calnexin, and erythrocyte marker, HBA. Silver staining revealed the protein loading amount
and the protein profile of each sample. (D-E) qPCR assays determined the expression levels of miR-144 in E-EVs from OSA patients (D), CIH-exposed mice (E), and their control
groups. Results are the means ± SEM (n = 4-6). *P < 0.05 vs. Nor E-EV or OSA E-EV. Two-tailed t test (D, E).

https://www.thno.org
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treatment (Figure 6C). Transcriptional factor hypoxia
inducible factor 1α (HIF-1α) plays a central role in
hypoxia status. We predicted the localization of two
hypoxia response elements (HREs) in the miR-144
promoter sequence and demonstrated that IH
treatment increased miR-144 promoter activity, which
was blocked by lentivirus-mediated knockdown of
Hif-1. Enhanced miR-144 promoter activity by Gata1
overexpression served as a positive control (Figure
6D). Furthermore, to evaluate the importance of
GATA1 and HIF-1α in miR-144 promoter activity, we
mutated GATA1 binding site on miR-144 promoter
and investigated the effect of intermittent hypoxia
and HIF-1α knockdown on the activity of the mutated
miR-144 promoter. Results indicated that although
intermittent hypoxia significantly induced miR-144
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wild type promoter activity, the mutated miR-144
promoter was insensitive to IH stimulation as well as
knockdown of Hif-1 (Figure 6E), suggesting that
GATA1 plays a more critical role than HIF-1α in
initiating miR-144 promoter activity. Accordingly, we
observed that upregulation of miR-144 by intermittent
hypoxia could be reversed by lentivirus-mediated
silencing of Hif-1 (Figure 6F) and upregulation of
miR-144 by HIF-1α overexpression was blocked by
knockdown of Gata1 (Figure 6G). Meanwhile,
intermittent hypoxia treatment and overexpression of
Hif-1 increased GATA1 expression in MEL cells,
which was blocked by Hif-1 knockdown (Figure
6H-I). These evidences indicated that miR-144 can be
directly regulated by HIF-1 or indirectly regulated
by HIF-1α/GATA1 pathway during hypoxia.

Figure 6. Expression and regulation of miR-144 in erythrocytes during intermittent hypoxia. (A-B) qPCR assay measured the expression level of pri-miRNA (A)
and miR-144 (B) in aortic endothelial cells and red blood cells in C57BL/6 mice under normoxia, CIH, or readministering normoxia for 15 days after 30-day-CIH treatment
(CIH-R-N). (C) The expression levels of miR-144 in MEL cells after continuous or intermittent hypoxia or DMOG (1mM in PBS, Hif-1α stabilizer) treatment for the indicated
period. (D) Luciferase reporter gene assays demonstrated the activity of the miR-144 promoter in IH- or normoxia-exposed 293A cells after Hif-1α knockdown or Gata1
overexpression by lentivirus infection. (E) Luciferase reporter gene assays demonstrated the activity of the wild-type miR-144 promoter (WT) or GATA1 binding site mutant
miR-144 promoter (Mut) in normoxia or IH-exposed 293A cells after lentivirus-mediated knockdown of Hif-1α. (F) The expression level of miR-144 in IH- or normoxia-treated
MEL cells after silencing Hif-1α. (G) The level of miR-144 in MEL cells after Gata1 knockdown or Hif-1α overexpression. (H) The levels of HIF-1α and GATA1 in IH- or
normoxia-treated MEL cells after lentiviral silencing of Hif-1α. (I) The levels of HIF-1α, and GATA1 in MEL cells after Gata1 knockdown or Hif-1α overexpression by lentivirus.
Results are the mean ± SEM (n = 4). *P < 0.05 vs. Nor (A-C, E, F, H) or Con (D, G, I). #P < 0.05 vs. CIH (A, B) or Hif-1α shRNA (D) or IH Scramble (E, F, H) or Hif-1α OE (G,
I). One-way ANOVA (C-I) and two-tailed t test (A, B).

https://www.thno.org

Theranostics 2022, Vol. 12, Issue 9

4245

Figure 7. Anti-miR-144 reverses CIH E-EV-induced superoxide anion overproduction, NRF2 decrease, and endothelial dysfunction. (A) qPCR analysis
verified the expression of miR-144 in H5V cells after the indicated E-EV treatment. (B) Protein levels of NRF2 and CAT in H5V cells treated with or without anti-miR-144-loaded
CIH E-EVs. Below panel depicted the relative levels of NRF2 and CAT. (C) En face fluorescence images with DHE staining revealed the superoxide level in aortic endothelial cells
after in vivo treatment with anti-Scr- or anti-miR-144-loaded CIH E-EVs. Bar, 20 µm. (D) Summary of the DHE fluorescence signal intensity. (E-F) Anti-miR-144-loaded CIH
E-EVs restored CIH E-EV-induced endothelial dysfunction in aortas under normoxia (E) or CIH (F). (G-H) antagomiR-144 in vitro 48-h treatment improved OSA E-EV- (G) or
CIH E-EV-(H) induced endothelial dysfunction. (I) Lentivirus-mediated overexpression of Nrf2 in mouse aortas reversed CIH E-EV-induced endothelial dysfunction. Results are
the mean ± SEM (n = 4). *P < 0.05 vs. Nor E-EV anti-Scr (A, B, D-F) or non-OSA E-EV (G) or Nor E-EV antagoScr (H) or Nor E-EV Lenti-Con (I). #P < 0.05 vs. CIH E-EV anti-Scr
(A, B, D-F) or OSA E-EV antagoScr (G) or CIH E-EV antagoScr (H) or CIH E-EV Lenti-Con (I). One-way ANOVA (A, B, D) and two-way ANOVA (E-I).

Anti-miR-144 blocked CIH E-EVs-induced
NRF2 expression, superoxide anion
production, and endothelial dysfunction
To further verify the endothelial effect of
miR-144 delivery by CIH E-EVs, anti-miR-144 as well
as anti-miR-144-loaded CIH E-EVs were utilized to
treat aortas in vitro or treat CIH mice in vivo. As
expected, anti-miR-144-loaded CIH E-EVs did not
increase miR-144 levels in H5V cells after incubation
for 48 h, while anti-scramble-loaded groups did
(Figure 7A). Protein levels of NRF2 and CAT in H5V
cells after 48-h treatment of anti-miR-144-loaded CIH
E-EVs were maintained at the level observed in the
control groups (Figure 7B). Consistently, in vivo CIH
E-EV treatment by tail injection (one injection/3 day,
for 12 days) potentiated superoxide anion production
in endothelial cells. However, this effect was largely
inhibited in anti-miR-144-loaded CIH E-EV treated

groups, as shown by en face DHE staining (Figure
7C-D). Meanwhile, in vivo treatment of CIH E-EVs
impaired EDR and increased systolic blood pressure
in normoxia- and CIH-treated mice. These effects
were reduced in groups treated with anti-miR-144loaded CIH E-EVs (Figure 7E-F and Figure S4C-E).
Similarly, antagomiR-144 significantly reversed
endothelial dysfunction caused by E-EV from CIH
mice or OSA patients (Figure 7G-H). Of note,
lentivirus-mediated
Nrf2
overexpression
also
effectively blocked CIH E-EV-impaired endothelial
function (Figure 7I).

Discussion
This study highlights the role of S-EVs and
E-EVs as blood-borne regulators of vascular function,
and pinpoints erythrocyte-enriched miR-144 as a
critical EV-derived miRNA that participates in
https://www.thno.org
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CIH-induced endothelial dysfunction via inhibiting
NRF2 expression.
OSA is a prevalent disease most frequently
associated with secondary hypertension [1].
Endothelial dysfunction is the earliest vascular
consequence of OSA or CIH and precedes
hypertension onset [22, 23]. However, the underlying
mechanism of OSA or CIH-induced endothelial
dysfunction is not well characterized. Some reports
propose that changes in vasoactive molecules, such as
reduced NO bioavailability [23], excessive oxidative
stress [24], increased levels of angiotensin II and
endothelin-1 [25, 26], regulate endothelial function
during the development of hypertension following
CIH. Consistently, we confirmed that CIH treatment
dramatically impaired EDR in the C57BL/6 mouse
aorta and increased systolic blood pressure. To
explore the mechanism more comprehensively and
systematically, we performed global transcriptome
analysis of aortas from CIH-treated mice. Among the
743 differentially expressed genes, Nrf2 was the only
one
commonly
implicated
in
the
four
vascular-associated responses, namely, contraction
and dilation, angiogenesis, ROS production, and
inflammation. ROS regulates vascular homeostasis,
and ROS overproduction-induced oxidative stress is a
primary cause of vascular dysfunction by reducing
NO availability [27]. Increased oxidative stress has
been proposed to contribute to OSA or CIH-related
endothelial dysfunction and hypertension. NRF2 is a
key antioxidant transcriptional factor with a
protective role in many free radical detoxification
pathways related to aging, atherosclerosis, hypertension, ischemia, and other cardiovascular diseases
[28, 29]. NRF2 binds to the antioxidant response
element to transcriptionally activate downstream
genes encoding Glutathione S-transferase, Aldehyde
dehydrogenase, CAT, Heme oxygenase 1, and
Thioredoxin [30]. However, most reports emphasize
the role of increased NOX levels and activity in
CIH-induced adverse vascular outcomes [24, 31], and
few studies have linked NRF2 regulation to
CIH-induced endothelial dysfunction, although some
studies similarly revealed that CIH inhibited NRF2
expression [4, 32]. In the present study, we
demonstrated that NRF2 downregulation in
CIH-treated mouse aorta or in CIH-treated
endothelial cells results in excess superoxide
production and impaired endothelial function, an
effect rescued by the NRF2 agonist, Oltipraz, or by the
ROS scavengers, Tempol or Tiron and DETCA. This
result confirms the importance of NRF2 in
CIH-associated endothelial dysfunction induced by
oxidative stress.
Circulating EVs are constantly in direct contact
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with and regulate the functions of endothelial cells
under pathophysiological conditions [33]. EVs from
OSA patient plasma impair endothelial adhesiveness
and permeability [34]. Little attention has been given
to the impact of EVs upon CIH-impaired EDR.
Flow-mediated dilation was attenuated in mice after
treatment with plasma EVs from OSA pediatric
patients. This compromised vascular function was
proposed to be caused by reduced eNOS expression
and altered EV miR-630 [35]. Our group recently
reported that EV derived from intermittent
hypoxia-treated red blood cells impaired endothelial
function through regulating eNOS phosphorylation
and ET-1 expression [11]. Here, we demonstrate that
EVs-derived from CIH S-EVs and CIH E-EVs
profoundly impaired EDR in normal mouse aorta.
Interestingly, NRF2 was differentially expressed in
CIH S-EV-treated HUVECs and CIH-treated mouse
aortas compared with their corresponding controls.
CIH S-EVs attenuated NRF2 expression, which
increased ROS production in endothelial cells without
altering NOX signaling. This was validated by
improved endothelial function in response to the
NRF2 agonist, Oltipraz.
We previously reported that S-EVs mediate
endothelial dysfunction in diabetes through delivery
of arginase 1 [8]. We also compared the S-EV protein
profiles between normoxic and CIH animal models,
but did not identify the possible differentially
expressed S-EV protein participating in CIH-induced
endothelial dysfunction [12]. Therefore, we focused
upon S-EV miRNAs through screening miRNAs
related to oxidative stress or hypoxia signaling in
S-EVs and found miR-144 and miR-27a was
upregulated in CIH S-EVs. miR-144 and miR-27a are
known to inhibit NRF2 expression by directly binding
to the 3′-UTR of Nrf2 [20], and we confirmed this
regulatory link in endothelial cells. Interestingly,
unlike miR-27a, miR-144 is expressed at a very low
endogenous level in endothelial cells. The expression
of miR-144 or pri-miR-144 in endothelial cells did not
change after intermittent hypoxia treatment,
suggesting that the increased level of miR-144 in CIH
S-EVs was likely to be derived from a non- endothelial
origin. miR-144 is highly expressed in erythrocytes
and is closely related to erythroid differentiation [21].
We confirmed high levels of miR-144 expression in
erythrocytes and E-EVs following CIH and in OSA.
miR-144 was reported to play versatile roles in
maintaining homeostasis in the cardiovascular
system. For instance, miR-144 significantly reduced
infarct size in an acute ischemia reperfusion injury
model and reduces left ventricular remodeling after
myocardial infarction through promoting autophagy
[36, 37], and protected against LPS-induced lung
https://www.thno.org
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endothelial hyperpermeability [38]; but it also
promoted atherosclerosis plaque formation [39], and
mediated the 7-Ketocholesterol-induced endothelial
dysfunction [40]. One research even found that
circulating exosomal miR-144-3p impaired the
mobilization ability of EPCs and then impaired
ischemia-induced neovascularization [9]. To clarify
the involvement of EV miR-144 in CIH E-EV-induced
endothelial dysfunction, we demonstrated that CIH
E-EV treatment increased miR-144 expression and
reduced NRF2 expression, increased superoxide
production in endothelial cells, attenuated aorta EDR,
and increased systolic blood pressure. Furthermore,
anti-miR-144-loaded CIH E-EVs effectively blocked
miR-144 expression and increased the levels of NRF2
and CAT in endothelial cells. More importantly,
functional studies revealed that anti-miR-144-loaded
CIH E-EVs as well as antagomir-144 partially rescued
EDR, reduced ROS, and decreased hypertension
caused by CIH E-EVs, indicating a pivotal role of
circulating EV miR-144 in these processes.
Furthermore, we confirmed the protective role of
NRF2 in CIH S-EV- or CIH E-EV-caused endothelial
dysfunction through overexpression of Nrf2 by
lentivirus.
The regulation of miR-144 in erythrocytes during
hypoxia is not well documented in the literature.
Sequencing analysis showed that miR-144 was
upregulated after 16 h of hypoxic treatment in
HUVECs [41]. Other papers have shown that miR-144
expression is significantly higher in cancer tissues that
are often under hypoxia conditions compared to
normal tissues [42, 43]. However, none of these
articles addressed the mechanism of hypoxia-induced
miR-144 upregulation. GATA1 is an important
transcriptional factor that increases miR-144
expression during erythropoiesis [44]. Here, we
predicated a hypoxia response element and a GATA1
binding site in the miR-144 promoter region and
confirmed that intermittent hypoxia treatment
promoted miR-144 expression in MEL cells via HIF-1α
direct transcriptional regulation. Interestingly, we
also demonstrated that both Hif-1 overexpression
and CIH treatment upregulated GATA1 expression in
MEL cells, indicating GATA1 to be a mediator
participating in HIF-1α indirect regulation of miR-144.
The present study has several limitations. In this
study, considering that OSA patients may have
complex comorbidities and complex pathophysiological states, which will increase the heterogeneity of
EVs and even lead to inconsistent results, we selected
serum EVs or erythrocyte-derived EVs obtained
under more consistent CIH conditions to treat aortic
and endothelial cells to obtain more reproducible
results. This result reflects the mechanism of
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EV-induced vascular impairment in CIH setting,
however, this mode of treatment is less clinically
relevant than EV of OSA patient origin. Meanwhile,
given that many of the miRNAs in mouse EVs are not
homologous to human ones, our treatment model
may therefore miss other possible functional
molecules. We provide clear evidence that miR-144 in
erythrocyte-derived EVs is responsible for endothelial
dysfunction induced by CIH, the major pathological
alteration in OSA. However, it is not known whether
the same or different EV miRNAs are involved in the
endothelial dysfunction induced by other pathological features of OSA, such as fragmented sleep,
sympathetic nerve activation, and increased negative
chest pressure. Moreover, we cannot exclude the
possible involvement of non-erythroid-derived
miR-144, albeit to a lesser degree. Further
investigation is warranted to address these problems.
Meanwhile, considering that mature erythrocytes
would not respond to any stimulus to induce the
expression of miRNAs, in the current work, we used
MEL to reveal the mechanism by which intermittent
hypoxia promoted miR-144 expression, which maybe
partially helped to understand the increased levels of
miR-144 in mature erythrocytes under CIH status,
however, the in vivo mechanism closer to the
physiological state should be in future investigations.
Due to technical constraints, the CIH paradigm used
in the current study does not closely match that
observed in clinical OSA status, new specific
interfering tools and more rigorous studies are
required to further explore the clinical relevance of
S-EV or E-EV in the development of OSA-related
vasculopathy. In addition, the present study cannot
discount other possible signals, such as miR-27a, that
are independent of E-EV miR-144/NRF2 might play a
role in CIH-induced impairment of endothelial
function, which requires future examination.
In summary, we systematically demonstrate that
CIH S-EVs and CIH E-EVs can deliver functional
miR-144 to endothelial cells, promoting superoxide
anion production by reducing NRF2 expression, a
critical pathogenic component of endothelial
dysfunction and hypertension during CIH. Our study
provides experimental evidence for the therapeutic
potential of EV-loaded anti-miR-144 or antagomir-144
in treating OSA or CIH-associated vascular
complications.
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